Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010
GlaxoSmithKline today issued the following statement in anticipation of the BBC Panorama programme, A risk worth taking which is scheduled to be aired this evening.
Read more -
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)
GlaxoSmithKline (GSK) continues to work in the best interest of diabetes patients who face this chronic and serious disease. Patients taking Avandia should speak with their doct...
Read more -
Reports of narcolepsy in Europe following vaccination with Pandemrix™
GSK initially became aware of possible cases of narcolepsy following vaccination with the adjuvanted H1N1 pandemic vaccine Pandemrix through adverse event reports received by th...
Read more -
GSK and Valeant announce new U.S. FDA PDUFA goal date for ezogabine
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug ...
Read more -
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
GlaxoSmithKline confirmed today that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the p...
Read more -
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta ...
Read more -
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top line results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refr...
Read more -
Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance
Detailed pictures have been published today showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments. The findings could ulti...
Read more -
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections
GlaxoSmithKline PLC (GSK) and Anacor Pharmaceuticals today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052, fo...
Read more -
GSK receives CHMP positive opinion for a new indication for Arixtra
GlaxoSmithKline (GSK) today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arixtra (fondap...
Read more -
GlaxoSmithKline statement in response to FDA announcement on TIDE trial
GlaxoSmithKline [NYSE: GSK] confirmed today that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical tria...
Read more -
GSK announces Q2 results for 2010
Q2 EPS before major restructuring* 2.6p (29.3p excluding pre-announced legal charge)
Read more -
GlaxoSmithKline legal update
GlaxoSmithKline (GSK) today announces that it expects to record a legal charge for the second quarter of 2010 of £1.57billion ($2.36 billion) (equating to an after tax cost of £...
Read more -
GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone)
GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Commit...
Read more -
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA
The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs' counsel in the product liability litigation. Th...
Read more -
Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia (rosiglitazone ma...
Read more -
GSK EU regulatory update on Avandia (rosiglitazone)
GlaxoSmithKline (GSK) today confirmed that on behalf of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP) is to review the benefit/r...
Read more -
GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore
GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB), the government agency responsible for economic growth and development, today jointly awarded funding fo...
Read more -
GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment,...
Read more -
GlaxoSmithKline creates a new operating unit dedicated to expanding access to medicines for people living in the world’s poorest countries
As part of its commitment to further transform the company’s approach to diseases that disproportionately affect the world’s poorest people, GlaxoSmithKline (GSK) to...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
